GSK3B and Alzheimer disease: We have previously shown that this neurotrophic peptide mixture is capable of reducing the behavioral deficits in APP tg mouse model of AD-like pathology [17, 18] by blocking CDK5 and GSK3β [41], resulting in decreased APP maturation and Aβ biosynthesis [41], increased neurogenesis [42] and synaptic formation [18, 41].